Aduhelm reignites ques­tions around ties be­tween phar­ma and pa­tient ad­vo­ca­cy orgs

In the lat­est round of pa­tient ad­vo­ca­cy and the FDA, the drug re­view­er ap­proved Bio­gen and Ei­sai’s Alzheimer’s dis­ease med Aduhelm over the ad­vice of its own ad­comm. Crit­ics point­ed to pres­sure from phar­ma-fund­ed ad­vo­ca­cy groups such as the Alzheimer’s As­so­ci­a­tion and its so­cial me­dia cam­paigns as de­cid­ing fac­tors. How­ev­er, the As­so­ci­a­tion and oth­er groups who spoke up for a treat­ment main­tain that they’re neu­tral and fo­cus on pa­tients’ needs and the need for treat­ment in the dev­as­tat­ing dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA